Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150)
Martin Reck, Mark A. Socinski, Federico Cappuzzo et al. · Annals of Oncology · 2017
Cited by 45 works. doi:10.1093/annonc/mdx760.002 Open-access PDF